The sector’s expansion is attributed to rising incidence rates. The triple-negative breast cancer (TNBC) market across the ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter’s investigational bispecific antibody ...

Last week, BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 ...

The analysts reiterated their Buy rating on BioNTech stock, citing the comprehensive clinical development program for BNT327 and the strategic benefits of the partnership.

A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.